Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)

  • Technology appraisal
  • TA703
  • Published: 

Register as a stakeholder

History

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators